Phaseline

Targets › LAG3

LAG3 (Lymphocyte activation gene 3 protein): drug programs, companies and trials

12 programs from 12 companies in 72 trials: 46 Phase 2, 20 Phase 1, 6 Phase 3; Oncology, Gastroenterology, Genitourinary; next expected readout Dec 2026.

[Lymphocyte activation gene 3 protein]: Inhibitory receptor on antigen activated T-cells. Delivers inhibitory signals upon binding to ligands, such as MHC class II, its main ligand present at the surface of antigen-presenting cells (APCs), and FGL1, which is secreted by hepatocytes and certain types of tumor cells. (UniProt, P18627)

Open in Phaseline: the race on LAG3, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
Bristol-Myers SquibbRelatlimab
Lymphocyte activation gene 3 protein inhibitor
LAG3Phase 3Non-small Cell Lung Cancer; Melanoma; Cancer; Urologic Neoplasms …Dec 2026
Regeneron PharmaceuticalsFianlimab (REGN3767)
Lymphocyte activation gene 3 protein inhibitor
LAG3Phase 3Melanoma; Advanced Non-Small Cell Lung Cancer; Head and Neck Squamous Cell Carcinoma (HNSCC); Resectable Non-small Cell Lung Cancer …Mar 2027
Merck & Co. (MSD)Favezelimab
Lymphocyte activation gene 3 protein inhibitor
LAG3Phase 3Solid Tumors; Metastatic Urothelial Carcinoma; Small Cell Lung CarcinomaMay 2027
Immutep S.A.S.eftilagimod alfa
Lymphocyte activation gene 3 protein vaccine antigen
LAG3Phase 3Advanced/Metastatic Non-Small Cell Lung Cancer (NSCLC); Neoadjuvant; Solid TumorsJun 2027
University of WashingtonTuparstobart
LAG-3 inhibitor monoclonal antibody
LAG3Phase 2Unresectable Clinical Stage III Merkel Cell Carcinoma AJCC v8Jan 2027
University Health Network, TorontoOpdualag (BMS-986213)
Anti-LAG3/anti-PD-1 bispecific antibody
LAG3, PDCD1Phase 2Cutaneous MelanomaFeb 2027
Shanghai Henlius BiotechHLX26
Anti-LAG-3 monoclonal antibody
LAG3Phase 2NSCLC Stage IVJul 2027
AkesoAK129
Bispecific antibody targeting LAG-3 and PD-1
LAG3, PDCD1Phase 1Advanced Malignant Tumors(Stage IA-IB); Non-small Cell Lung Cancer Stage IIIB/IV; Classic Hodgkin LymphomaDec 2026
RocheRO7247669
Anti-PD-1 and anti-LAG-3 bispecific antibody
PDCD1, LAG3Phase 1Solid TumorsJun 2027
Shenyang Sunshine PharmaceuticalSSGJ-709
Bispecific antibody targeting PD-1 and LAG-3
PDCD1, LAG3Phase 1Advanced Malignant TumorsSep 2027
Australian & New Zealand Children's Haematology/Oncology GroupOpdualag
PD-1 and LAG-3 inhibitor combination
PDCD1, LAG3Phase 1Childhood CancerDec 2030
University Medical Center Groningen89Zr-DFO-REGN3767
Anti-LAG-3 PET imaging tracer
LAG3Phase 1Metastatic Solid Tumor–

Conditions

Melanoma (9) Non-small Cell Lung Cancer (3) Solid Tumors (3) Head and Neck Squamous Cell Carcinoma (HNSCC) (2) Advanced Melanoma (2) Renal Cell Carcinoma (2) Colorectal Cancer (2) Basal Cell Carcinoma (2) Cutaneous Melanoma (2) Advanced Non-Small Cell Lung Cancer (1) Resectable Non-small Cell Lung Cancer (1) Advanced Malignancies (1)

Modalities

antibody (5), small molecule (4), mixed (3)

Companies

Regeneron Pharmaceuticals (1) Merck & Co. (MSD) (1) Bristol-Myers Squibb (1) Roche (1) Immutep S.A.S. (1) Akeso (1) University Health Network, Toronto (1) Shenyang Sunshine Pharmaceutical (1) University Medical Center Groningen (1) University of Washington (1) Australian & New Zealand Children's Haematology/Oncology Group (1) Shanghai Henlius Biotech (1)

Related targets

PDCD1 (5)

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.